RecruitingNCT05397392
Research on Optimal Diagnosis and Treatment of Cardiorenal Syndrome
Sponsor
Nanjing First Hospital, Nanjing Medical University
Enrollment
1,200 participants
Start Date
Jan 1, 2016
Study Type
OBSERVATIONAL
Conditions
Summary
To estimate the characteristics, pathogenesis, risk factors and intervention measures for different stages of heart and kidney diseases, and to optimize the curative effects of different treatment schemes
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is researching the best ways to diagnose and treat cardiorenal syndrome — a condition where the heart and kidneys affect each other's function, leading to both failing at the same time or one after the other.
**You may be eligible if...**
- You have been diagnosed with one of the five types of cardiorenal syndrome, including acute heart failure causing kidney injury, chronic heart disease causing chronic kidney disease, acute kidney injury affecting the heart, or chronic kidney disease affecting the heart
**You may NOT be eligible if...**
- You do not meet the diagnostic criteria for cardiorenal syndrome
- You are unable or unwilling to provide informed consent
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERguideline recommended routine treatment
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05397392
Related Trials
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288653 locations
Impact of Optimized Pacing Strategies on Clinical and Hemodynamic Outcomes in Heart Failure Patients With Pacemaker
NCT075631531 location
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370638 locations
The Salt Study for Heart Failure
NCT075605921 location
HARMONY Trial : To Evaluate a Therapeutic and Monitoring Device(NOVAtria System) for Heart Failure Management
NCT074022391 location